COMORBID STATUS AND FACTORS THAT NEGATIVE INFLUENCE ON THE COURSE OF MYELOMA DISEASE DEPENDING ON THE SEASON OF THE YEAR IN THE REPUBLIC OF TAJIKISTAN
MUSTAFAKULOVA N.I., MIRZOKARIMOVA N.S., KAMOLOVA G.N., ABDULLAEVA S.N., KHOLOVA SH.K.
Department of Internal Diseases №3 of the Avicenna Tajik State Medical University
Aim. To study the comorbid status and negatively influencing risk factors on the course of myeloma disease (MD) depending on the season of the year in the Republic of Tajikistan.
Material and Methods. 130 patients with MD from the age of 63 to 77 years were under observation. The average age was 70,0 years. In all three groups, men predominated.
All patients with MD were divided according to the season of admission: in summer (n=63; 48,4%), in autumn (n = 7; 5,3%), in winter (n = 23; 17,6%), in spring (n = 37; 28,4%). According to the level of comorbidity, patients were divided into 3 groups: I – with a low level (n = 20), II with an average level (n = 33) and the III group – with a high level (n = 77). There were 77 patients in stage II and 53 in stage III.
Results. Patients in the III (terminal) stage had a severe course and a high level of comorbidity with the prevalence of hemorrhagic, anemic, intoxication and diarrheal syndromes with the addition of infectious complications. The highest frequency of hospitalized patients and a severe course of MD were observed in the hot summer season compared with the cold time (2,7 times more). In the hot season, compared with the cold, increased skin loss of fluid, significantly decreased concentrations of mineral salts in the blood: sodium (107,0±0,05 mmol/l and 137,0±1,7) and potassium (2,6±0,15 and 3,7±0,05) mmol/l, while the concentration of calcium in plasma was elevated (8,3±0,17 and 3,3±0,17 mmol/l)
Conclusion. The hot summer season, comorbidity, toxicity of chemotherapeutic agents, infectious complications, mineral metabolism disorders, aggravate the course of MD and impair it prognosis.
Key words: myeloma disease, comorbidity, cardiotoxicity, chemotherapy
1. Poddubnaya I. V., Savchenko V. G., Al-Radi L. S., Sovremennaya onkologiya: Rossiyskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevaniy [Modern oncology: Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases]. Moscow, Meditsina Publ., 2013. 55.
2. Strugov V. V., Stadnik E. A., Virts Yu. V., Silina T. O., Zaritskiy A. Yu. Znachenie vozrasta i soputstvuyushchikh zabolevaniy v terapii khronicheskogo limfoleykoza [Role of patient’s age and comorbidities in therapy of chronic lymphocytic leukemia]. Klinicheskaya Onkogematologiya .[Clinical Oncohematology]. 2016; 2: 162-168.
3. Mustafakulova N.I., Kamolova G.N. Trudnosti diagnostiki vtorichnoy artropatii I osnovnikh klinicheskikh sindromov mielomnoy bolezni [Difficulties in diagnosing secondary arthropathy and major clinical syndromes of myeloma]. Vestnik Avicenni [Вестник Авиценны]. 2018; 20(4):351-356.
4. Baldomero H., Gratwohl A., The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant. 2011; 46: 485-501.
5. Chesi M. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013; 3: 13-23.
6. Kleber M., Ihorst G., Udi J., Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and ofadditional comorbidities by comorbidity apprai-sal. Clin. Lymphoma Myeloma Leuk. 2012; 12. (1): 38-48.
7. Kachuri L., Demers A., Blair J. J., Spinelli M. Multiple pesticide exposures and the risk of multiple myeloma in Canadian men. Int J Cancer. 2013; 8: 46-58.
8. San-Miguel J. F. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book. 2013; 10: 12-15.
9. Sung Min Kim, Moon Jin Kim, Hyun Ae Jung, Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. Biomed Res Int. 2014; 2014: 437852.
Information about authors:
Mustafakulova Namuna Ibragimovna – Head of the Department of Internal Diseases №3 of the Avicenna Tajik State Medical University, Doctor of Medical Sciences, Associate Professor; tel.: (+992)918762494; e-mail: email@example.com
Mirzokarimova Nasiba Salimovna – Applicant at the Department of Internal Diseases №1 of the Avicenna Tajik State Medical University
Kamolova Guldzhakhon Negmatovna – Doctor of the Department of Internal Diseases №3 of the Avicenna Tajik State Medical University
Abdullaeva Sitora Navruzovna – Doctor of the Department of Internal Diseases №3 of the Avicenna Tajik State Medical University
Kholova Shakhnoza Kudratovna – Doctor of the Department of Internal Diseases №3 of the Avicenna Tajik State Medical University